NattoPharma’s Mission: Moving Vitamin K2 From “Novel” To Mainstream
This article was originally published in The Tan Sheet
Norwegian firm NattoPharma has found that educating firms about the health benefits of vitamin K2 is a crucial part of growing its business and finding dietary supplement manufacturers to use its proprietary MenaQ7 ingredient.
You may also be interested in...
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.